Almac Announces Collaborative Study with Pfizer and the PETACC3 Translational Research Working Party (PTRW)
CRAIGAVON, NORTHERN IRELAND-May 21, 2009)-Almac Diagnostics has today announced a collaborative study between Almac, Pfizer and the PETACC3 Translational Research Working Party (PTRW) The study involves gene expression profiling of formalin-fixed paraffin-embedded (FFPE) samples from the Pan-European Trials in Adjuvant Colon Cancer (PETACC 3) trial using Almac Diagnostic's unique Colorectal Cancer DSA(TM) research tool to identify molecular subtypes, biomarkers and drug targets.
Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States and Europe and is the second most common cause of cancer mortality in both sexes.
The samples to be used in the study are taken from the PETACC 3 study, an international randomized, prospective trial of adjuvant chemotherapy in patients with stage II and III colon cancer. This study represents a unique resource in advancing the molecular understanding of colon cancer.
Prof. Paul Harkin, President and Managing Director of Almac Diagnostics stated "As understanding grows of the heterogeneity of cancer, it is becoming increasingly clear that molecular subtypes are important both in patients' prognosis and in predicting their response to chemotherapy. This has already been shown in breast cancer, and the study to be led by Almac, Pfizer and PTRW aims to examine this in colorectal cancer."
The aims of the study are to identify molecular subtypes in colorectal cancer and to identify new drug targets in treatment resistant patients.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
